Literature DB >> 17011615

Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas.

Khush Mittal1, Alla Joutovsky.   

Abstract

The pathogenesis of uterine leiomyosarcomas (LMS) is poorly understood. It is unknown if these tumors arise de-novo or from pre-existing leiomyomata (LM) or atypical leiomyomata. In this study, we evaluated morphologic heterogeneity within uterine LMS to identify possible precursor lesions. We reviewed 11 cases of total hysterectomy in which the final diagnosis was LMS. All slides from the grossly recognized tumor were evaluated for the degree of atypia and mitotic counts within the leiomyosarcomas. The slides with the lowest and highest mitotic count were stained with monoclonal antibody to p53, MIB-1 and ER/PR. The number of cells stained was subjectively assessed to nearest 5%, with 1% for rare positive cells. Morphologically benign tumor areas were identified in 5 of the 11 tumors. These areas showed <5 mitoses/10 HPF, with 1+ atypia in 4 cases and 1-2+ atypia in 1 case. No necrosis was seen by definition. Immunostains could be done in 4 of these 5 cases. These morphologically benign areas showed a p53 expression of 1% in each of the 4 cases, with low MIB-1 (5 to 15%) and high ER/PR expression (ER: 50-100%, PR: 10-100%). Morphologically malignant areas had 13 to 31 mitoses/10 HPF, 2+ to 3+ atypia, p53 expression of 70% to 100%, MIB-1 expression of 40% to 100%, ER expression of 1 to 100% and PR expression of 1 to 100%. The benign and malignant areas merged in all cases. Morphologic and immunohistochemical spectrum of changes from benign to malignant is seen in 50% of LMS. This raises the possibility of progression of some leiomyomata to LMS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011615     DOI: 10.1016/j.ygyno.2006.08.034

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

Review 1.  Malignant tumors of the uterine corpus: molecular background of their origin.

Authors:  D Brany; D Dvorska; M Nachajova; P Slavik; T Burjanivova
Journal:  Tumour Biol       Date:  2015-08-26

Review 2.  Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids.

Authors:  Burkhard Helmke; Joern Bullerdiek; Carsten Holzmann; Wolfgang Kuepker; Birgit Rommel
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

3.  MED12 alterations in both human benign and malignant uterine soft tissue tumors.

Authors:  Gaëlle Pérot; Sabrina Croce; Agnès Ribeiro; Pauline Lagarde; Valérie Velasco; Agnès Neuville; Jean-Michel Coindre; Eberhard Stoeckle; Anne Floquet; Gaëtan MacGrogan; Frédéric Chibon
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

4.  Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.

Authors:  Netta Mäkinen; Kati Kämpjärvi; Norma Frizzell; Ralf Bützow; Pia Vahteristo
Journal:  Mol Cancer       Date:  2017-06-07       Impact factor: 27.401

5.  MR Imaging of a Leiomyosarcoma Arising in Leiomyoma.

Authors:  Shinya Fujii; Masaki Tsuda; Naoko Mukuda; Kanae Nosaka; Shinya Sato; Toshihide Ogawa
Journal:  Magn Reson Med Sci       Date:  2018-11-02       Impact factor: 2.471

6.  Dedifferentiated leiomyosarcoma of the uterus with heterologous elements: a potential diagnostic pitfall.

Authors:  Kojo R Rawish; Oluwole Fadare
Journal:  Case Rep Obstet Gynecol       Date:  2012-10-17

7.  DNA fragmentation factors 40 and 45 (DFF40/DFF45) and B-cell lymphoma 2 (Bcl-2) protein are underexpressed in uterine leiomyosarcomas and may predict survival.

Authors:  Tomasz Banas; Kazimierz Pitynski; Krzysztof Okon; Aleksandra Czerw
Journal:  Onco Targets Ther       Date:  2017-09-14       Impact factor: 4.147

8.  Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with ALK rearrangement and loss of 14q.

Authors:  Carsten Holzmann; Christian Saager; Gunhild Mechtersheimer; Dirk Koczan; Burkhard M Helmke; Jörn Bullerdiek
Journal:  Oncotarget       Date:  2018-06-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.